$ORGO
Organogenesis Holdings Inc.

2020 Q4 Form 10-Q Financial Statement

#000119312520289119 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $106.8M $100.8M $68.96M
YoY Change 43.16% 56.85% 6.18%
Cost Of Revenue $25.50M $22.96M $20.04M
YoY Change 25.0% 20.04% 3.06%
Gross Profit $81.30M $77.84M $48.92M
YoY Change 49.72% 72.45% 7.51%
Gross Profit Margin 76.12% 77.22% 70.94%
Selling, General & Admin $53.20M $51.15M $46.50M
YoY Change 1.53% 3.38% -5.01%
% of Gross Profit 65.44% 65.71% 95.06%
Research & Development $6.300M $3.709M $4.668M
YoY Change 75.0% -5.48% 20.81%
% of Gross Profit 7.75% 4.77% 9.54%
Depreciation & Amortization $2.200M $956.0K $891.0K
YoY Change -6.38% 20.71% 3.73%
% of Gross Profit 2.71% 1.23% 1.82%
Operating Expenses $59.50M $54.86M $51.17M
YoY Change 6.25% 2.73% -3.13%
Operating Profit $21.80M $22.98M -$2.252M
YoY Change -1382.35% -378.04% -69.23%
Interest Expense -$2.900M $2.969M $2.912M
YoY Change 11.54% 22.33% 33.15%
% of Operating Profit -13.3% 12.92%
Other Income/Expense, Net $0.00 -$1.974M -$2.887M
YoY Change -18.7% 25.14%
Pretax Income $18.90M $21.01M -$5.139M
YoY Change -529.55% -296.45% -46.61%
Income Tax $400.0K $72.00K $27.00K
% Of Pretax Income 2.12% 0.34%
Net Earnings $18.50M $20.93M -$5.166M
YoY Change -520.45% -294.9% -46.46%
Net Earnings / Revenue 17.32% 20.77% -7.49%
Basic Earnings Per Share $0.20
Diluted Earnings Per Share $141.0K $0.19 -$49.67K
COMMON SHARES
Basic Shares Outstanding 107.8M 105.0M 106.1M
Diluted Shares Outstanding 108.5M

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.40M $36.50M $40.50M
YoY Change 40.2% 58.7% 102.5%
Cash & Equivalents $84.81M $36.89M $40.75M
Short-Term Investments
Other Short-Term Assets $5.300M $5.700M $4.700M
YoY Change 65.63% 72.73% 46.88%
Inventory $27.80M $29.88M $28.56M
Prepaid Expenses $4.935M
Receivables $56.80M $56.92M $44.02M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $174.3M $129.0M $117.7M
YoY Change 38.81% 59.58% 54.58%
LONG-TERM ASSETS
Property, Plant & Equipment $60.07M $55.94M $53.03M
YoY Change 27.31% 26.4% 30.14%
Goodwill $28.77M $28.92M $25.54M
YoY Change 12.66% 13.22% 0.0%
Intangibles $30.62M $31.85M $19.16M
YoY Change 47.24% 42.73% -19.63%
Long-Term Investments
YoY Change
Other Assets $670.0K $700.0K $728.0K
YoY Change -24.21% -23.58% -30.0%
Total Long-Term Assets $120.2M $117.4M $98.78M
YoY Change 26.36% 25.18% 7.45%
TOTAL ASSETS
Total Short-Term Assets $174.3M $129.0M $117.7M
Total Long-Term Assets $120.2M $117.4M $98.78M
Total Assets $294.5M $246.4M $216.5M
YoY Change 33.44% 41.11% 28.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $23.38M $24.01M $29.94M
YoY Change -17.63% -15.02% 34.41%
Accrued Expenses $23.97M $26.13M $24.69M
YoY Change 2.23% 26.82% 19.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $20.30M $15.10M $10.00M
YoY Change 554.84% 420.69% 316.67%
Total Short-Term Liabilities $68.22M $66.25M $66.06M
YoY Change 13.9% 16.77% 31.07%
LONG-TERM LIABILITIES
Long-Term Debt $64.50M $99.60M $105.3M
YoY Change 29.95% 1.63% 165.49%
Other Long-Term Liabilities $7.971M $8.802M $8.264M
YoY Change 19.88% 37.72% 32.86%
Total Long-Term Liabilities $7.971M $8.802M $8.264M
YoY Change -85.84% 37.72% -81.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $68.22M $66.25M $66.06M
Total Long-Term Liabilities $7.971M $8.802M $8.264M
Total Liabilities $148.4M $181.0M $180.7M
YoY Change -10.11% 11.82% 24.75%
SHAREHOLDERS EQUITY
Retained Earnings -$150.8M -$171.6M -$192.5M
YoY Change -11.84% 2.97% 24.01%
Common Stock $296.8M $237.0M $228.2M
YoY Change 31.0% 32.11% 27.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $728.5K $728.5K
Shareholders Equity $146.1M $65.47M $35.75M
YoY Change
Total Liabilities & Shareholders Equity $294.5M $246.4M $216.5M
YoY Change 33.44% 41.11% 28.8%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income $18.50M $20.93M -$5.166M
YoY Change -520.45% -294.9% -46.46%
Depreciation, Depletion And Amortization $2.200M $956.0K $891.0K
YoY Change -6.38% 20.71% 3.73%
Cash From Operating Activities $26.28M $7.140M -$9.340M
YoY Change -510.62% -230.77% -22.87%
INVESTING ACTIVITIES
Capital Expenditures -$8.890M -$5.850M -$2.170M
YoY Change 157.68% 357.03% 83.9%
Acquisitions
YoY Change
Other Investing Activities $400.0K -$4.380M $290.0K
YoY Change
Cash From Investing Activities -$8.480M -$10.23M -$1.880M
YoY Change 145.8% 699.22% 59.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.12M -770.0K 4.890M
YoY Change -36.01% -107.91% 74.64%
NET CHANGE
Cash From Operating Activities 26.28M 7.140M -9.340M
Cash From Investing Activities -8.480M -10.23M -1.880M
Cash From Financing Activities 30.12M -770.0K 4.890M
Net Change In Cash 47.92M -3.860M -6.330M
YoY Change 28.75% -229.1% -39.66%
FREE CASH FLOW
Cash From Operating Activities $26.28M $7.140M -$9.340M
Capital Expenditures -$8.890M -$5.850M -$2.170M
Free Cash Flow $35.17M $12.99M -$7.170M
YoY Change -1292.2% -410.77% -34.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Cash
Cash
36512000
CY2019Q4 us-gaap Cash
Cash
60174000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
129010000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
125600000
CY2020Q3 us-gaap Assets
Assets
246428000
CY2019Q4 us-gaap Assets
Assets
220687000
CY2020Q3 orgo Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
26132000
CY2019Q4 orgo Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
23450000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
66245000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59894000
CY2020Q3 us-gaap Liabilities
Liabilities
180954000
CY2019Q4 us-gaap Liabilities
Liabilities
165104000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
237015000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
226580000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171552000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171007000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
65474000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
55583000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
246428000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220687000
CY2020Q3 us-gaap Revenues
Revenues
100799000
CY2019Q3 us-gaap Revenues
Revenues
64265000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
22980000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8265000
us-gaap Operating Income Loss
OperatingIncomeLoss
5644000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27705000
us-gaap Profit Loss
ProfitLoss
-545000
us-gaap Profit Loss
ProfitLoss
-36056000
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
22964000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
19131000
CY2020Q3 us-gaap Gross Profit
GrossProfit
77835000
CY2019Q3 us-gaap Gross Profit
GrossProfit
45134000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51146000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
49475000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3709000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3924000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
54855000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
53399000
CY2020Q3 us-gaap Interest Expense
InterestExpense
2969000
CY2019Q3 us-gaap Interest Expense
InterestExpense
2427000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
44000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1974000
us-gaap Revenues
Revenues
231491000
us-gaap Revenues
Revenues
186336000
us-gaap Cost Of Revenue
CostOfRevenue
61799000
us-gaap Cost Of Revenue
CostOfRevenue
55557000
us-gaap Gross Profit
GrossProfit
169692000
us-gaap Gross Profit
GrossProfit
130779000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
150261000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
147325000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13787000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11159000
us-gaap Operating Expenses
OperatingExpenses
164048000
us-gaap Operating Expenses
OperatingExpenses
158484000
us-gaap Interest Expense
InterestExpense
8391000
us-gaap Interest Expense
InterestExpense
6392000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1862000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
90000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
20934000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-1286000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2428000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-318000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21006000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10693000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
72000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
48000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
20934000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-10741000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6055000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8243000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
134000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108000
us-gaap Net Income Loss
NetIncomeLoss
-545000
us-gaap Net Income Loss
NetIncomeLoss
-36056000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
35750000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
23198000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-109000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-242000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
47041000
orgo Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
-628000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-163000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-700000
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
374000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
196000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
56915000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39359000
CY2020Q3 us-gaap Inventory Net
InventoryNet
29882000
CY2019Q4 us-gaap Inventory Net
InventoryNet
22918000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5327000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2953000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55937000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47184000
CY2019Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
556000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31849000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20797000
CY2020Q3 us-gaap Goodwill
Goodwill
28916000
CY2019Q4 us-gaap Goodwill
Goodwill
25539000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
700000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
884000
CY2020Q3 orgo Deferred Acquisition Consideration Liability Current
DeferredAcquisitionConsiderationLiabilityCurrent
966000
CY2019Q4 orgo Deferred Acquisition Consideration Liability Current
DeferredAcquisitionConsiderationLiabilityCurrent
5000000
CY2020Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
11667000
CY2020Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3473000
CY2019Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3057000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
24007000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
28387000
CY2020Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
39353000
CY2019Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
33484000
CY2020Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1098000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1012000
CY2020Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
12239000
CY2019Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
14431000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8802000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6649000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-10741000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
12808000
us-gaap Depreciation
Depreciation
2749000
us-gaap Depreciation
Depreciation
2553000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2518000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4526000
orgo Non Cash Interest Expense
NonCashInterestExpense
160000
orgo Non Cash Interest Expense
NonCashInterestExpense
196000
orgo Deferred Interest Expense
DeferredInterestExpense
1577000
orgo Deferred Interest Expense
DeferredInterestExpense
974000
orgo Non Cash Rent Expense Income
NonCashRentExpenseIncome
33000
orgo Non Cash Rent Expense Income
NonCashRentExpenseIncome
606000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2559000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-29000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-201000
us-gaap Share Based Compensation
ShareBasedCompensation
1164000
us-gaap Share Based Compensation
ShareBasedCompensation
700000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1862000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
19160000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-553000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7757000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7840000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2262000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
699000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3778000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5348000
orgo Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
3521000
orgo Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
85000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
878000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-715000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19475000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27127000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12260000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2526000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16354000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2776000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
5869000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
7000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
17585000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1286000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
163000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
924000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12345000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31657000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23484000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1754000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60370000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21405000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36886000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23159000
us-gaap Interest Paid
InterestPaid
7130000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171552000
us-gaap Interest Paid
InterestPaid
5922000
us-gaap Income Taxes Paid
IncomeTaxesPaid
110000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
91000
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3021000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3049000
CY2020Q3 orgo Working Capital
WorkingCapital
62765000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7179636
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1553723
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.04
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
638315
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
630399
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.64
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7464645
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.27
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.60
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.16
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
250000
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
10000000
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
50000000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
628000
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
6762000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1776000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
863000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2628000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3698000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
500000
us-gaap Net Income Loss
NetIncomeLoss
-545000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19475000
CY2020Q3 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
1013000
CY2020Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
62040000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
42408000
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
5125000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3049000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3928000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3420000
CY2020Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1589000
CY2019Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-56000
CY2020Q3 orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-392000
CY2019Q3 orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-30000
orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-483000
orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-456000
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
5125000
CY2019Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2935000
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9676000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9178000
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1499000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
781000
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
18707000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12959000
CY2020Q3 orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
315000
CY2019Q3 orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
286000
orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
2024000
orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
809000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
86967000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
82774000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
68559000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y2M12D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12701000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
65812000
CY2020Q3 us-gaap Depreciation
Depreciation
956000
CY2019Q3 us-gaap Depreciation
Depreciation
792000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
28916000
CY2019 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
25539000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
885000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1529000
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
46400000
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14551000
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
31849000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32830000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12033000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20797000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21158000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17640000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4974000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5810000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26132000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23450000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
16667000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
20000000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
99353000
CY2020Q3 orgo Shares Reserved For Issuance For Outstanding Options
SharesReservedForIssuanceForOutstandingOptions
6788655
CY2019Q4 orgo Shares Reserved For Issuance For Outstanding Options
SharesReservedForIssuanceForOutstandingOptions
6503646
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14427352
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15512642
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
486000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
242000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1164000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1623000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5512393
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7062928
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
12835000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
387000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
538000
CY2020Q3 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1198000
CY2020Q3 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
4786000
CY2020Q3 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
4945000
CY2020Q3 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
9825000
CY2020Q3 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
5042000
CY2020Q3 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
15712000
CY2020Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3473000
CY2020Q3 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
43850000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1620000
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1766000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4971000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4993000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1250000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1224000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
5974000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3471000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2804000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6899000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
21622000
CY2020Q3 orgo Accrued Legal Expenses
AccruedLegalExpenses
158000
CY2019Q4 orgo Accrued Legal Expenses
AccruedLegalExpenses
542000
CY2017 orgo Business Combinationdeferred Consideration Payment
BusinessCombinationdeferredConsiderationPayment
2500000
CY2019Q4 orgo Business Combination Deferred Consideration
BusinessCombinationDeferredConsideration
5000000
CY2020Q3 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
0
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
16000
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
127000
CY2020Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
47999000
CY2019Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
49634000
orgo Gain Loss On Deferred Acquisition Consideration Settlement
GainLossOnDeferredAcquisitionConsiderationSettlement
2246000
orgo Gain Loss On Deferred Acquisition Consideration Settlement
GainLossOnDeferredAcquisitionConsiderationSettlement
2246000
orgo Adjustment For Excess And Obsolete Inventories
AdjustmentForExcessAndObsoleteInventories
-2024000
orgo Adjustment For Excess And Obsolete Inventories
AdjustmentForExcessAndObsoleteInventories
-809000
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
1726000
orgo Payments Of Deferred Acquisition Consideration
PaymentsOfDeferredAcquisitionConsideration
3034000
CY2019Q3 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
880000
us-gaap Administrative Fees Expense
AdministrativeFeesExpense
2810000
us-gaap Administrative Fees Expense
AdministrativeFeesExpense
1991000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
42686000
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
728548
CY2020Q3 orgo Shares Reserved For Issuance For Outstanding Restricted Stock Units
SharesReservedForIssuanceForOutstandingRestrictedStockUnits
819248
CY2020Q3 orgo Shares Reserved For Issuance For Future Grant
SharesReservedForIssuanceForFutureGrant
6819449
CY2019Q4 orgo Shares Reserved For Issuance For Future Grant
SharesReservedForIssuanceForFutureGrant
9008996
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
873595
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
54347
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.69
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
819248
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.82
CY2019 orgo Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Options Outstanding Weighted Average Remaining Contractual Terms
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOptionsOutstandingWeightedAverageRemainingContractualTerms
P5Y21D
orgo Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Options Outstanding Weighted Average Remaining Contractual Terms
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOptionsOutstandingWeightedAverageRemainingContractualTerms
P5Y6M10D
us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
4000000
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
2000000
CY2020Q3 orgo Remaining Litigation Settlement Amount Payable
RemainingLitigationSettlementAmountPayable
2000000
CY2020Q3 orgo Remaining Litigation Settlement Amount Payable Per Quarter
RemainingLitigationSettlementAmountPayablePerQuarter
500000
CY2020Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1295000
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Central Index Key
EntityCentralIndexKey
0001661181
dei Entity Registrant Name
EntityRegistrantName
Organogenesis Holdings Inc.
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Trading Symbol
TradingSymbol
ORGO
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
107785526
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Small Business
EntitySmallBusiness
true
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108185702
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105599434
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107457154
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104870886
CY2020Q3 orgo Deferred Acquisition Consideration Noncurrrent
DeferredAcquisitionConsiderationNoncurrrent
1436000
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3782000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2020Q3 orgo Gain Loss On Deferred Acquisition Consideration Settlement
GainLossOnDeferredAcquisitionConsiderationSettlement
951000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-411000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35948000
CY2019Q3 orgo Deemed Dividends To Warrant Holders
DeemedDividendsToWarrantHolders
-645000
orgo Deemed Dividends To Warrant Holders
DeemedDividendsToWarrantHolders
-645000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
20934000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11386000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-545000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36701000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105040035
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92276858
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104748297
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91182233
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108489768
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92276858
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104748297
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91182233
CY2020Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
7986000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
7986000
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure as of the date of the consolidated financial statements and the reported results of operations during the reporting period. Actual results could differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
orgo Deemed Dividends To Warrant Holders
DeemedDividendsToWarrantHolders
-645000
CY2020Q3 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
3377000
CY2020Q3 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
13570000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
5820000
orgo Deferred Acquisition Consideration And Earnout Liability For Business Acquisition
DeferredAcquisitionConsiderationAndEarnoutLiabilityForBusinessAcquisition
5218000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
973000
us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
1111000
orgo Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued
7986000
CY2020Q3 us-gaap Capital Leases Future Minimum Payments Net Minimum Payments1
CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1
20754000
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3782000
CY2019Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
30890748
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0046
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0224
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3742
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.427
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
4.04
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
7.08
CY2020Q3 orgo Fair Value Of Common Share
FairValueOfCommonShare
3.37
CY2019Q3 orgo Fair Value Of Common Share
FairValueOfCommonShare
7.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-486000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-1164000
CY2020Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
951000
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2009245
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12855000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20799000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7263990
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8283893
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7263990
dei Security12b Title
Security12bTitle
Class A Common Stock, $0.0001 par value

Files In Submission

Name View Source Status
0001193125-20-289119-index-headers.html Edgar Link pending
0001193125-20-289119-index.html Edgar Link pending
0001193125-20-289119.txt Edgar Link pending
0001193125-20-289119-xbrl.zip Edgar Link pending
d17599d10q.htm Edgar Link pending
d17599dex311.htm Edgar Link pending
d17599dex312.htm Edgar Link pending
d17599dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
orgo-20200930.xml Edgar Link completed
orgo-20200930.xsd Edgar Link pending
orgo-20200930_cal.xml Edgar Link unprocessable
orgo-20200930_def.xml Edgar Link unprocessable
orgo-20200930_lab.xml Edgar Link unprocessable
orgo-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending